Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation
Virna Cortez-Retamozo, … , Ralph Weissleder, Mikael J. Pittet
Virna Cortez-Retamozo, … , Ralph Weissleder, Mikael J. Pittet
Published November 6, 2008
Citation Information: J Clin Invest. 2008;118(12):4058-4066. https://doi.org/10.1172/JCI36335.
View: Text | PDF
Technical Advance Immunology

Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation

  • Text
  • PDF
Abstract

Eosinophils are multifunctional leukocytes that degrade and remodel tissue extracellular matrix through production of proteolytic enzymes, release of proinflammatory factors to initiate and propagate inflammatory responses, and direct activation of mucus secretion and smooth muscle cell constriction. Thus, eosinophils are central effector cells during allergic airway inflammation and an important clinical therapeutic target. Here we describe the use of an injectable MMP-targeted optical sensor that specifically and quantitatively resolves eosinophil activity in the lungs of mice with experimental allergic airway inflammation. Through the use of real-time molecular imaging methods, we report the visualization of eosinophil responses in vivo and at different scales. Eosinophil responses were seen at single-cell resolution in conducting airways using near-infrared fluorescence fiberoptic bronchoscopy, in lung parenchyma using intravital microscopy, and in the whole body using fluorescence-mediated molecular tomography. Using these real-time imaging methods, we confirmed the immunosuppressive effects of the glucocorticoid drug dexamethasone in the mouse model of allergic airway inflammation and identified a viridin-derived prodrug that potently inhibited the accumulation and enzyme activity of eosinophils in the lungs. The combination of sensitive enzyme-targeted sensors with noninvasive molecular imaging approaches permitted evaluation of airway inflammation severity and was used as a model to rapidly screen for new drug effects. Both fluorescence-mediated tomography and fiberoptic bronchoscopy techniques have the potential to be translated into the clinic.

Authors

Virna Cortez-Retamozo, Filip K. Swirski, Peter Waterman, Hushan Yuan, Jose Luiz Figueiredo, Andita P. Newton, Rabi Upadhyay, Claudio Vinegoni, Rainer Kohler, Joseph Blois, Adam Smith, Matthias Nahrendorf, Lee Josephson, Ralph Weissleder, Mikael J. Pittet

×

Figure 4

In vivo FMT for detection of treatment response.

Options: View larger image (or click on image) Download as PowerPoint
In vivo FMT for detection of treatment response.
(A) Structure of dexame...
(A) Structure of dexamethasone (D). (B) Structures of the self-activating viridin prodrug (S; R = CH3) and control nonactivating compound (N; R = H). (C) Protocol of procedures and treatment regimen. (D and E) FMT informs on treatment efficacy. Dexamethasone (orange) and self-activating viridin prodrug (green) suppressed eosinophil-associated MMP activity in lung compared with control mice treated with vehicle dextran alone (V; red) or control nonactivating compound (gray). Unchallenged mice (blue) served as controls. (F) Ex vivo analysis of digested lungs. Administration of dexamethasone or self-activating viridin prodrug decreased the number of lung eosinophils. (G) Flow cytometry analysis of digested lungs revealed that administration of self-activating viridin prodrug, and, to a lesser extent, dexamethasone, decreased MMP activity of eosinophils on a per-cell basis. ND, not done. At least 2 independent experiments were performed, with n = 3–5 per experiment and per group. Data are mean ± SEM. *P < 0.05, **P < 0.01 versus OVA-challenged, vehicle dextran–treated control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts